Navigation Links
Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
Date:2/13/2013

NEW YORK, Feb. 13, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released fourth quarter 2012 U.S. prescription sales data for the top 100 drugs.

At the close of 2012, Otsuka's antipsychotic Abilify overtakes AstraZeneca's acid reducer Nexium and moves into the number one spot with over $1.47 billion in quarterly sales. Sales expanded for all five front-runners over the quarter, although none reached double-digit growth. There are no changes in the top selling pharmaceutical classes, which include antipsychotics, proton pump inhibitors, and statins.Top Five Drugs by Sales, Q4 2012Drug Name  

Gain ($000)  

% Change (previous quarter)budesonide$79,295

+42.52%Abilify$73,075

+5.20%Cymbalta$69,131

+5.97%Lantus Solostar

$62,028

+11.58%Advair Diskus$56,263

+4.90%Top Five Sales Losses, Q4 2012Drug Name

Gain ($000)% Change (previous quarter)TriCor-$128,731

-41.58%Neulasta-$29,497

-3.54%Incivek-$26,778

-9.14%One Touch Ultra

-$24,687

-6.59%Avonex-$20,275

-5.17%AbbVie's cholesterol treatment TriCor drops 53 spots with a $129 million sales decline in Q4 2012 even though it did not lose patent protection until January of 2013. Neulasta, Incivek and Avonex also report declining sales of $20 to $30 million.

"The top five brands maintained their leading positions in the last quarter of 2012." said Philip Thornton , CEO of Drugs.com. "Fewer blockbuster brands lost exclusivity, however 2013 will bring a new round of generic competition highlighted by the expected Cymbalta patent loss later this year."

Zomig and Aciphex are additional top-selling brands expected to lose patent protection in 2013.

Detailed data on the top 100 drugs can be accessed at: 
http://www.drugs.com/stats/top100/sales

About Drugs.com

Drugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, January 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: www.drugs.com

Media Inquiries: 
Drugs.com Press Officer 
press@drugs.com 
(718) 395 2473

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
2. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
3. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
4. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
5. ShelfX Releases A Fridge That Knows What You Took
6. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
7. Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
8. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
9. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
10. MD Bioproducts releases HLA-B27 subtype specific antibody.
11. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... -- James Gilbart , ... 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ...      ... in a supplement to European Oncology & Haematology ... by James Gilbart and Axel ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a ... has been life-saving as she has been on the trial for more than six ... ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Angel”: ... the Lord has set out for each of his children. “The Angel” is the ... School of Music in New York City, and impassioned writer. , When asked of ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
Breaking Medicine News(10 mins):